2nd Non-Opioid Pain Therapeutics Summit

Memo

One year on from Vertex Pharmaceuticals' milestone JOURNAVX® approval, making history as the first new class of pain medicine in decades, non-opioid pain R and D has skyrocketed as one of biopharma's hottest areas for innovation and investment, projected to hit $124bn by 2034. M and A headlines, including Eli Lilly's $1bn+ acquisitions of SiteOne Therapeutics and 4E Therapeutics, AbbVie's $745m licensing deal with Haisco Pharmaceutical, continue to fuel the pain innovation flywheel. As companies race to build on the first major clinical validation of the space, attention is rapidly expanding beyond sodium channels as a 'silver bullet' toward neuroimmune pathways, neurotrophin biology, GLP-1 signaling, potassium channels, gene regulation, and other emerging mechanisms. Bringing together 150+ senior leaders across pain biology, drug discovery, translational science, clinical development, medical affairs, business development, venture capital, and patient advocacy, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals, Eli Lilly, AbbVie, Grunenthal, Xenon Pharmaceuticals, Levicept, Tonix Pharma, Maxona Pharmaceuticals, 4E Therapeutics, NIH, Harvard Medical School, and leading investment firms to explore emerging mechanisms, new clinical data, trial design innovations, placebo mitigation strategies, translational models, patient-centered development approaches, and the investment trends shaping the future of pain therapeutics. URLs:Tickets: https://go.evvnt.com/3860905-2?pid=5569Brochure: https://go.evvnt.com/3860905-3?pid=5569 Prices:Drug Developer Pricing - Full Access Pass (Conference + Workshop Day): USD 3897.00,Drug Developer Pricing - 3 Day Pass (Conference + 1 Workshop): USD 3348.00,Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2799.00,Academic Pricing - Full Access Pass (Conference + Workshop Day): USD 3297.00,Academic Pricing - 3 Day Pass (Conference + 1 Workshop): USD 2848.00,Academic Pricing - 2 Day Pass (Conference Only): USD 2399.00,Service Provider Pricing - Full Access Pass (Conference + Workshop Day): USD 5397.00,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3999.00 Speakers: Erica Bial, Medical Director, Clinical Development Pain, Vertex Pharmaceuticals, Darrell Henze, Executive Director, Merck and Co., Inc., Ana Moreno, Founder and Chief Executive Officer, Navega Therapeutics, Jana Obajdin, Analyst, Biogeneration Ventures, James Gilligan, President and Chief Scientific Officer, Entropy Neurodynamics (formerly Tryp Therapeutics), James Campbell, President and Chief Scientific Officer, Centrexion, Florian Jakob, Head of Drug Discovery Engine, Grunenthal, Bryan Moyer, Senior Vice President, Discovery, Latigo Biotherapeutics, John Dyer, Managing Director, Aquilo, Shawn Fatholahi, President and Chief Executive Officer, MAXONA Pharmaceuticals, Chris Kenney, Chief Medical Officer, Xenon Pharmaceuticals, Roman Camarda, Principal, Novo Holdings, Shuai Li, Founder and Chief Executive Officer, Shanghai SimR Biotechnology, Kavya Gopal, Senior Vice President and Disease Area Executive for Pain, Vertex Pharmaceuticals, John Markman, Vice President, Global Pain, Eli Lilly, Vincent Nadeau, Principal, BSquared Capital, Sigal Meilin, Chief Scientific Officer, MD Biosciences, Ted Price, Co-Founder of 4E Therapeutics and Professor, 4E Therapeutics, UT Dallas, Paul Negulescu, Senior Vice President, Disease Area, Vertex Pharmaceuticals, Emilio Quetglas, Senior Director, Medical and Clinical Development, Tris Pharma, Peter Borden, Director, Search and Evaluation, AbbVie, Stephen Zicha, Senior Director, Neuroscience, Eli Lilly, William Housley, Head of Rheumatology Early Discovery (Immunology R and D), AbbVie, Errol Gould, Senior Vice President, Medical Affairs, TONIX Pharmaceuticals, Simon Westbrook, Founder and Chief Scientific Officer, Levicept, Bruce Bean, Professor, Harvard, Cindy Steinberg, Director, Policy and Advocacy, US Pain Foundation, Cliff Woolf, Director, FM Kirby Neurobiology Centre, Boston Children's Hospital, Luana Colloca, Interim Chair, Pain and Translational Symptom Science, University of Maryland, Michael Oshinsky, Director, Preclinical Pain Research, NIH Category: Conferences | Science, Health and Medicine | Pharmaceuticals Date and Time: 26th January 2027 at 8:00 am to 28th January 2027 at 5:20 pm Venue details: Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, 02128, United States